The NVIDIA-Eli Lilly $1 billion partnership is already setting new industry standards, potentially triggering a wave of similar high-value collaborations across the sector.
These companies are at the forefront of using artificial intelligence to solve healthcare's biggest challenges, from drug discovery to personalised treatments.
Early investors in AI-powered healthcare could benefit as this technology transforms how we develop medicines and treat diseases worldwide.
The $1 billion NVIDIA and Eli Lilly partnership marks a pivotal moment where artificial intelligence meets pharmaceutical innovation. This collaboration signals that AI is becoming fundamental to modern drug discovery, creating opportunities for companies that can harness computational power to accelerate medical breakthroughs and transform healthcare outcomes.
This group spans from technology giants providing AI infrastructure to biotech innovators using machine learning for drug development. These companies represent a high-growth sector where computational biology, precision medicine, and automated analysis are revolutionising how we discover and develop new treatments for complex diseases.
Each company has been handpicked by professional analysts for their strategic position at the intersection of AI and healthcare. They range from established pharmaceutical leaders actively investing in AI capabilities to emerging specialists using proprietary platforms to solve complex therapeutic challenges through computational innovation.
NVIDIA and Eli Lilly have launched a $1 billion AI lab to revolutionize the drug discovery process. This partnership highlights a burgeoning investment opportunity in companies at the intersection of artificial intelligence and biotechnology.
This basket's total market cap is 5,994,886.71147 and its value is heavily concentrated in a few very large-cap holdings that anchor the portfolio. Roughly 92% of the total market cap sits in the two largest positions, indicating a top-heavy weighting that tends to reduce volatility but limits diversification.
NVDA: $4.49T
LLY: $1.02T
REGN: $80.72B
+7
์ด ๋ฐ์ค์ผ์ ์ ์ฒด ์คํ ๋ฆฌ๋ฅผ ํ์ธํ์ธ์. ๋ฆฌ์คํฌ์ ์ ์ฌ๋ ฅ์ ๋ค๋ฃฌ ์์ธ ๊ธฐ์ฌ๋ฅผ ์ฝ์ด๋ณด์ธ์.
์ธ์ฌ์ดํธ ์ ์ฒด ์ฝ๊ธฐ
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitiv Ltd.
์ด ์์ฐ๋ค์ ํฌ์ํ๋ค๋ฉด:
12๊ฐ์ ํ ์์ ๊ฐ์น:
+233.50%
์ ๋๋ฆฌ์คํธ๋ค์ ์ด ๊ทธ๋ฃน์ ์์ฐ์ด ํฅํ 1๋ ๊ฐ ํ๊ท 233.5% ์ฑ์ฅํ ๊ฒ์ผ๋ก ์์ํฉ๋๋ค.
์ด ๊ทธ๋ฃน์ ์์ฐ 16๊ฐ ์ค 15๊ฐ๊ฐ ์ ๋ฌธ ์ ๋๋ฆฌ์คํธ๋ก๋ถํฐ ๋งค์ ์๊ฒฌ์ ๋ฐ์์ต๋๋ค.
Here are a few of the assets in this group. Create an account to unlock the full list.
REGENERON PHARMACEUTICALS INC
REGN
ํ์ฌ๊ฐ
$814.16
Regeneron utilises its proprietary VelociSuite technologies, which integrate large-scale genetic data and automation, aligning with AI-driven approach...
Regeneron utilises its proprietary VelociSuite technologies, which integrate large-scale genetic data and automation, aligning with AI-driven approaches to accelerate drug development.
Join Nemo FREE today and unlock every stock
60์ด๋ฉด ์ถฉ๋ถํฉ๋๋ค.
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
